Feature | Women's Health | July 08, 2015

Study Suggests Benefits of Mammography Alone Overestimated

Countries that started widescale screening programs earlier found to have similar breast cancer mortality rates to those that started later

mammography, benefits overestimated, Royal Society of Medicine, breast cancer

July 8, 2015 - An in-depth review of randomized trials on screening for various cancers, published in the Journal of the Royal Society of Medicine, shows that the benefits of mammographic screening are likely to have been overestimated. This overestimation results from the use of an unconventional statistical method which differs from that used for other cancer screening trials, concludes the paper co-authored by researchers at King's College London and the University of Strathclyde Institute of Global Public Health at iPRI, France.

The review examined screening methods for breast, colorectal, cervical, prostate and lung cancers.

Started in the 1960s and 70s, the Swedish randomized trials suggested that mammography screening could reduce breast cancer mortality by 20-25 percent in populations where screening is widespread. These findings were, and remain, extremely influential in decisions taken to establish population breast cancer screening programs using mammography.

The goal of cancer screening is principally to reduce the mortality from the disease in question by enabling cancers to be found at an early stage. Early detection reduces the risk of being diagnosed with an advanced cancer that is often deadly. In 2002, the World Health Organization (WHO) recommended that when population screening for breast cancer was implemented in any region, the rate of advanced breast cancers should be monitored: If the program is successful, these rates should show a fall over time, indicating that mammography screening is contributing effectively to reducing breast cancer mortality. Moreover, with increased screening, more rapid and more pronounced falls in breast cancer mortality would be expected in countries that implemented mammography screening programs at the end of the 1980s than in countries that implemented programs ten to fifteen years later.

"Contrary to expectations, numerous studies in North America, Europe and Australia have shown that the rates of advanced breast cancer have not declined in countries where most women regularly attend mammography screening" observed Prof. Philippe Autier, lead author from University of Strathclyde Institute of Global Public Health at iPRI. He went on to note that "other studies have shown that declines in breast cancer mortality were the same in countries that implemented mammography screening end of the 1980s as those that did so ten to twenty years later. The absence of differences in mortality reductions could not be explained by differences in access to modern therapies."

Prof. Richard Sullivan, from the Institute of Cancer Policy, King's College London, observed that "these findings were in sharp contrast with screening for cervical and colorectal cancers, two cancers for which studies have clearly shown the capacity of screening to reduce the numbers of advanced cancers in populations. This has major implications for policy-makers in middle income countries who are now making decisions about where to prioritize cancer screening efforts."

These discrepancies led Autier and his colleagues to undertake an in-depth review of all randomized trials of cancer screening. He concluded that "if the Swedish trials had used similar statistical analyses to other cancer screening trials, reductions in the risk of breast cancer death associated with mammography screening would have been much smaller, probably less than 10 percent."

"The reduction seen in the mortality from breast cancer in many countries is one of the major contributions to cancer control in recent times" noted Peter Boyle, professor and director of the University of Strathclyde Institute of Global Public Health at iPRI. "Many factors have contributed to this success, including earlier presentation and better diagnosis, as well as major improvements in the organization of care (multidisciplinary teams) to specific improvements in surgery, radiotherapy and chemotherapy/endocrine therapy. Currently, assessment of the impact of mammographic screening programs cannot be made without taking advances in breast cancer treatment into account."

For more information: www.jrs.sagepub.com

Related Content

Contrast-Enhanced Ultrasound Safe and Effective Detector of Liver Cancer
News | Ultrasound Imaging | October 19, 2017
Doctors can effectively detect liver cancer with ultrasound and tiny microbubbles, according to a study announced at...
Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Overlay Init